You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Temozolomide

Showing 1 - 25 of 1,157
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

Pheochromocytoma, Metastatic, Paraganglioma, Malignant, Pheochromocytoma Malignant Trial in Beijing (Temozolomide capsule)

Completed
  • Pheochromocytoma, Metastatic
  • +2 more
  • Temozolomide capsule
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
May 4, 2023

Pheochromocytoma, Paraganglioma Trial in Beijing (Temozolomide)

Recruiting
  • Pheochromocytoma
  • Paraganglioma
  • Temozolomide
  • Beijing, China
    Peking Union Medical College Hospital
May 22, 2023

Neuroendocrine Tumors Trial in Beijing (Surufatinib Combined With Temozolomide and S-1)

Not yet recruiting
  • Neuroendocrine Tumors
  • Surufatinib Combined With Temozolomide and S-1
  • Beijing, Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 8, 2023

Melanoma Stage III Trial in Shanghai (Toripalimab combined with Temozolomide)

Not yet recruiting
  • Melanoma Stage III
  • Toripalimab combined with Temozolomide
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 23, 2023

Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma Trial in Padova (Regorafenib, Temozolomide)

Recruiting
  • Glioblastoma, IDH-wildtype
  • MGMT-Methylated Glioblastoma
  • Padova, Italy
    Istituto Oncologico Veneto IRCCS
Oct 18, 2023

Recurrent Glioblastoma Trial in Beijing (Laser interstitial thermal therapy, Temozolomide)

Active, not recruiting
  • Recurrent Glioblastoma
  • Laser interstitial thermal therapy
  • Temozolomide
  • Beijing, China
    Beijing Tiantan Hospital
Dec 22, 2022

Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))

Active, not recruiting
  • Glioblastoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023

Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme Trial in Cleveland (Eflornithine (Dose Level 1), Eflornithine

Recruiting
  • Glioblastoma, IDH-wildtype
  • +4 more
  • Eflornithine (Dose Level 1)
  • +3 more
  • Cleveland, Ohio
    The Cleveland Clinic
May 19, 2023

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III Trial in San Antonio, Zuerich (Debio 0123,

Not yet recruiting
  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
  • Astrocytoma, Grade III
  • Debio 0123
  • +2 more
  • San Antonio, Texas
  • +1 more
Mar 9, 2023

Recurrent Glioblastoma Trial (Sintilimab plus Bevacizumab and Temozolomide)

Not yet recruiting
  • Recurrent Glioblastoma
  • Sintilimab plus Bevacizumab and Temozolomide
  • (no location specified)
Nov 27, 2022

MGMT-Unmethylated Glioblastoma Trial (Etoposide Plus Cisplatin)

Not yet recruiting
  • MGMT-Unmethylated Glioblastoma
  • Etoposide Plus Cisplatin
  • (no location specified)
Jan 12, 2023

Ewing Sarcoma Trial in Beijing (Vincristine, Temozolomide)

Recruiting
  • Ewing Sarcoma
  • Beijing, Beijing, China
    Peking University People's Hospital
Oct 31, 2022

Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV) Trial in Baltimore (Chemotherapy with Temodar.,

Terminated
Has Results
  • Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV)
  • Chemotherapy with Temodar.
  • Radiation therapy
  • Baltimore, Maryland
    Ummc Msgcc
Dec 1, 2022

Gastrointestinal Stromal Tumors Trial in Seoul (Temozolomide capsule)

Not yet recruiting
  • Gastrointestinal Stromal Tumors
  • Temozolomide capsule
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Dec 14, 2022

Glioblastoma Multiforme Trial in Seoul (BEY1107, Temozolomide)

Recruiting
  • Glioblastoma Multiforme
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Mar 13, 2023

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Aug 21, 2022

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Recurrent Extensive Stage Small Cell Lung Carcinoma Trial in Hangzhou, Nanjing, Zhengzhou (HTMC0435, Temozolomide)

Not yet recruiting
  • Recurrent Extensive Stage Small Cell Lung Carcinoma
  • Hangzhou, China
  • +2 more
Feb 5, 2023

Neuroendocrine Tumors, Frailty, Chemo Effect Trial in Milan (Temozolomide capsule)

Recruiting
  • Neuroendocrine Tumors
  • +2 more
  • Temozolomide capsule
  • Milan, Italy
    European Institute of Oncology, IEO, IRCCS
Sep 21, 2022

Glioblastoma Multiforme (GBM) Trial in Taoyuan (ADI-PEG20, Temozolomide)

Recruiting
  • Glioblastoma Multiforme (GBM)
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou Branch
Sep 29, 2022

Glioblastoma Trial run by the NCI (drug, biological, other)

Completed
  • Glioblastoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 23, 2022

Glioblastoma Multiforme Trial in Baltimore (Retifanlimab, Temozolomide, Radiation Therapy)

Recruiting
  • Glioblastoma Multiforme
  • Baltimore, Maryland
    Johns Hopkins Medical Institution
Dec 5, 2022

Recurrent Pituitary Adenomas Trial in New York (Capecitabine, Temozolomide)

Terminated
Has Results
  • Recurrent Pituitary Adenomas
  • New York, New York
    Weill Cornell Medical College
Jul 15, 2022

Recurrent High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma Trial (PCI 24781, Temozolomide)

Not yet recruiting
  • Recurrent High Grade Glioma
  • +4 more
  • PCI 24781
  • Temozolomide
  • (no location specified)
Jan 24, 2023